AUTHORS
Rashmi Tresa Philpose, MBBS, Khadijah Adel Hassan Mahmoud Moustafa, MBBS2, Michele Cottler-Fox, MD3, David Raggay, MD4, V Rakesh Sethapati, MD5, Gina Drobena, MD6, Aaron Wyble, MD7
AFFILIATIONS
1 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
2 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
3 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
4 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
5 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
6 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
7 University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
ABSTRACT
INTRODUCTION:
Autologous hematopoietic progenitor cell (aHPC) products are cryopreserved up to 72 hours after collection. Some transplant centers cryopreserve cells at very high nucleated cell (NC) concentrations without seeing severe adverse infusion events or delays in engraftment after transplant (Rowley SD et al. Blood 1994), others adjust NC concentration to ≤2 x108/mL (Lanza F et al. Trans Aph Sci 2020) to avoid infusion events or ≤4 x108/mL (Wuchter, P. EBMT Handbook 2024) to optimize viability if cryopreservation occurs later than 24 hours after collection. Comparison of CD34+ cell concentrations versus NC concentrations are unavailable.
METHODS:
We examined cell therapy lab processing and autologous stem cell transplant (ASCT) infusion records from January 2025 to December 2025. All aHPC products were processed <24 hours after collection, with no target NC/mL prior to or during freezing. Cells were centrifuged, plasma removed, and freeze mix containing crystalloid (Plasma-Lyte A), human serum albumin, and dimethyl sulfoxide (DMSO, 10% final concentration) was added. Up to 95mL/bag was frozen using a controlled-rate freezer then stored in vapor-phase liquid nitrogen.
ASCT data were compared based on NC/mL of aHPC products as follows: ≤2 x108 NC/mL (NC≤2), >2 to ≤4 x108 NC/mL (NC>2 to ≤4), and >4 x108 NC/mL (NC>4). Statistical analysis was performed using ANOVA (Kruskal-Wallis) with post hoc multiple comparisons (Dunn’s test).
Data collected included: patient demographics (age, sex, and diagnosis); product characteristics (NC/mL, % CD34, and CD34/mL); transplant characteristics (ASCT dose of CD34/kg and duration of cryostorage); and engraftment data (day of neutrophil [WBC] engraftment and day of platelet [PLT] engraftment).
RESULTS:
A total of 154 patients underwent 180 ASCT, with 55 ASCT in NC≤2 group (median 1.48, range 0.68 – 2 x108 NC/mL), 67 ASCTs in NC>2 to ≤4 group (median 3.1, range 2.025 – 4 x108 NC/mL), and 58 ASCT in the NC>4 group (median 4.82, range 4.004 – 6.613 x108 NC/mL), all NC/mL comparisons were significant (P < .01). Patient age and sex were similar between groups. NC>4 had significantly fewer diagnoses of plasma cell dyscrasia (PCD) (NC≤2: 100% PCD; NC>2 to ≤4: 95.5% PCD; NC>4: 82.8% PCD; P < .05 for all comparisons vs. NC>4).
There were no significant differences in transplant dose (NC≤2: median 5.7, range 3.5 – 12.5 x106 CD34/kg; NC>2 to ≤4: median 5.5, range 2.4 – 13.6 x106 CD34/kg; NC>4: median 4.9, range 1.2 – 11.1 x106 CD34/kg; P > .05), time to WBC engraftment (NC≤2: median 11, range 10 – 13 days; NC>2 to ≤4: median 11, range 9 – 13 days; NC>4: median 11, range 9 – 14 days; P > .05), or PLT engraftment (NC≤2: median 17, range 14 – 24 days; NC>2 to ≤4: median 17, range 13 – 28 days; NC >4: median 17, range 11 – 23 days; P > .05). Duration of cryostorage prior to transplant was significantly shorter in the NC>4 vs. NC≤2 (NC≤2: median 127, range 16 – 1245 days; NC>2 to ≤4: median 82, range 8 – 1796 days; NC>4: median 47, range 12 – 3539 days; NC>4 vs. NC≤2, P < .01, other comparisons not significant).
The aHPC CD34+ cell concentration was significantly lower at cryopreservation in the NC>4 group (NC≤2: median 5.41, range 3.13 – 11.35 x106 CD34/mL; NC>2 to ≤4: median 5.75, range 1.38 – 12.6 x106 CD34/mL; NC>4: median 3.41, range 0.31 – 12.62 x106 CD34/mL; P < .01 for all comparisons vs. NC>4). The % CD34 by flow cytometry of HPC grafts was different for all comparisons, decreasing as the NC/mL increased (NC≤2: median 4.35, range 1.76 – 10.55 % CD34; NC>2 to ≤4: median 2.08, range 0.35 – 5.27 % CD34; NC>4: median 0.72, range 0.05 – 2.57 % CD34; P < .01 for all comparisons). There were no severe infusion-related adverse events during this study period.
CONCLUSION:
Engraftment kinetics were not affected by NC concentration or CD34+ cell concentration for transplanted aHPC grafts. The CD34+ cell concentration was lowest in the >4 x108 NC/mL group, and the % CD34 decreased as the NC/mL increased, suggesting that institutions without NC concentration limits for their cryopreserved HPC grafts may have inversely proportional relationships between NC concentration and CD34+ cell concentration. Cell therapy laboratories may cryopreserve products safely at higher concentrations within 24 hours of collection, to optimize storage space without impacting engraftment. If adverse effects of infusion are noted at higher concentrations, it may be that infusion protocols need to be examined for potential impact.
DISCLOSURES
Rashmi Tresa Philpose, MBBS: No relevant conflicts of interest to declare.